Your browser doesn't support javascript.
loading
Menstrual management in developmentally delayed adolescent females.
Chuah, Irene; McRae, Alexandra; Matthews, Kim; Maguire, Ann M; Steinbeck, Katharine.
  • Chuah I; Department of General Medicine, The Children's Hospital at Westmead, The Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
  • McRae A; Academic Department of Adolescent Medicine, The Children's Hospital at Westmead, The Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
  • Matthews K; Department of Adolescent Medicine, The Children's Hospital at Westmead, The Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
  • Maguire AM; Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, The Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
  • Steinbeck K; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Aust N Z J Obstet Gynaecol ; 57(3): 346-350, 2017 Jun.
Article en En | MEDLINE | ID: mdl-28299789
ABSTRACT

BACKGROUND:

Requests for assistance in menstrual management and menstrual suppression are a common, emotive and sometimes controversial aspect of adolescent disability care.

AIMS:

To review the uptake and outcomes of menstrual suppression among adolescent patients with developmental delay.

METHODS:

A retrospective review of the medical records of adolescent females with intellectual disability referred for menstrual management to the Paediatric and Adolescent Gynaecology Clinic, Children's Hospital at Westmead, Sydney, for the three-year period between January 1, 2010 and January 1, 2013.

RESULTS:

Eighty adolescent patients with developmental delay were identified. A third (n = 28) of the patients were pre-menarcheal at first review with parent/caregivers seeking anticipatory advice. Of the post-menarcheal patients, the median age of menarche was 12 years (range 10-15 years). First and second line interventions were documented as were reasons for change where applicable. The combined oral contraceptive pill (COCP) was the most frequently used therapy (67%), and 19 patients in total had a levonorgestrel releasing intrauterine system (LNG-IUS) inserted (31%). Our study population differs from similar previously published groups in the marked absence of the use of depot medroxyprogesterone acetate or the subdermal etonogestrel releasing device.

CONCLUSION:

As a paediatrician, it is important to address menstrual management issues and allay caregiver concerns with appropriate advice. Our study supports the use of the COCP as sound first line management in achieving menstrual suppression. The LNG-IUS appears to be a favourable second line option. Further investigation into longer-term outcomes and potential complications of device insertion is recommended.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Discapacidades del Desarrollo / Levonorgestrel / Anticonceptivos Orales Combinados / Dispositivos Intrauterinos Medicados / Menstruación Tipo de estudio: Observational_studies Límite: Adolescent / Child / Female / Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Discapacidades del Desarrollo / Levonorgestrel / Anticonceptivos Orales Combinados / Dispositivos Intrauterinos Medicados / Menstruación Tipo de estudio: Observational_studies Límite: Adolescent / Child / Female / Humans Idioma: En Año: 2017 Tipo del documento: Article